N

New England Cancer Specialists | Scarborough, ME

Research site
(Unclaimed)
Location
100 Campus Drive Suite 108, Scarborough, Maine, United States of America

Site insights

Top conditions

Top treatments

Atezolizumab
Trastuzumab
Pembrolizumab
Everolimus
Sacituzumab
Enfortumab
Estrogen
Capivasertib
Ribociclib
Idasanutlin

Parent organization

This site is a part of New England Cancer Specialists

Data sourced from clinicaltrials.gov

Work at this site?

CTV for research professionals allows users to enhance their site’s profile, add contact information, and more.

Learn more and claim site

Active trials

15 of 16 total trials

A Phase III, Open-Label Study of Maintenance Lurbinectedin in Combination With Atezolizumab Compared With Atezolizumab in Participants With Extensive-Stage Small-Cell Lung Cancer (IMforte)

Study GO43104 is a Phase III, randomized, open-label, multicenter study of lurbinectedin in combination with atezolizumab compared with atezolizumab...

Active, not recruiting
Small-Cell Lung Cancer
Drug: Atezolizumab
Drug: Lurbinectedin
Recently updated

This is a global, multicenter, open-label safety extension study. Participants receiving single-agent trastuzumab emtansine or trastuzumab emtansine...

Enrolling
Neoplasm Metastasis
Drug: Trastuzumab
Drug: Pertuzumab

This is a Phase III, two-arm, randomized, double-blind placebo-controlled study in participants with HER2-positive primary breast cancer who have rec...

Enrolling
Breast Cancer
Drug: Trastuzumab Emtansine
Drug: Placebo

This Phase III, randomized, open-label, multicenter study will evaluate the efficacy and safety of giredestrant plus everolimus compared with the phy...

Enrolling
Estrogen Receptor (ER)-Positive, HER2-negative, Locally Advanced or Metastatic Breast Cancer
Drug: Fulvestrant
Drug: Dexamethasone Mouth Rinse

This is an open-label, multicenter, non-randomized extension and long-term observational study. Participants receiving atezolizumab monotherapy or at...

Active, not recruiting
Cancer
Drug: Atezolizumab
Drug: Bevacizumab
Locations recently updated

This is an open-label, multicenter, extension study. Patients who are receiving clinical benefit from atezolizumab monotherapy or atezolizumab in com...

Enrolling
Cancer
Drug: Emactuzumab
Drug: Niraparib

This 2-arm, randomized, open-label study will evaluate the efficacy and safety of trastuzumab emtansine versus trastuzumab as adjuvant therapy in pat...

Active, not recruiting
Breast Cancer
Drug: trastuzumab
Drug: trastuzumab emtansine

This is a Phase III, randomized, open-label multicenter study that will evaluate the efficacy and safety of giredestrant compared with fulvestrant, b...

Enrolling
Estrogen Receptor-Positive, HER2-Negative Advanced Breast Cancer
Diagnostic Test: FoundationOne Liquid CDx Assay (F1LCDx)
Drug: Giredestrant
Locations recently updated

This research study is studying how well newly diagnosed breast cancer that has tested positive for a protein called HER2 responds using one of two d...

Enrolling
Breast Cancer
HER2-positive Breast Cancer
Drug: Paclitaxel
Drug: trastuzumab-emtansine

This is a study of perioperative pembrolizumab or enfortumab vedotin in combination with pembrolizumab in participants who are cisplatin-ineligible o...

Active, not recruiting
Urinary Bladder Cancer, Muscle-invasive
Procedure: Surgery (radical cystectomy (RC) plus Pelvic Lymph Node Dissection [PLND])
Drug: Pembrolizumab
Locations recently updated

A Randomized, Double-blind, Multi-center, Phase III Clinical Study of AK112 or Placebo Combined With Pemetrexed and Carboplatin in Patients With EGFR...

Enrolling
Non-Squamous Non-small Cell Lung Cancer
Drug: Placebo Injection
Drug: AK112 Injection

The primary hypothesis is that pembrolizumab/vibostolimab (MK-7684A) in combination with chemotherapy is superior to pembrolizumab in combination wit...

Active, not recruiting
Metastatic Non-Small Cell Lung Cancer
Biological: Pembrolizumab
Drug: Cisplatin

The goal of this study is to find out if the experimental product, sacituzumab govitecan-hziy (SG) in combination with pembrolizumab given after surg...

Enrolling
Triple Negative Breast Cancer
Drug: Capecitabine
Drug: Sacituzumab govitecan-hziy (SG)

This is a Phase III, global, multicenter, open-label, randomized study to compare the efficacy and safety of 16 cycles (1 cycle duration=21 days) of...

Active, not recruiting
Non-Small Cell Lung Cancer
Drug: Gemcitabine
Drug: Pemetrexed

TAPISTRY is a Phase II, global, multicenter, open-label, multi-cohort study designed to evaluate the safety and efficacy of targeted therapies or imm...

Enrolling
Solid Tumors
Drug: Atezolizumab
Drug: Trastuzumab emtansine

Trial sponsors

Roche logo
Genentech logo
Merck Sharp & Dohme (MSD) logo
Dana-Farber Cancer Institute logo
Gilead Sciences logo
Stemline Therapeutics logo
Summit Therapeutics logo

Clinical trials

Find clinical trialsTrials by location
© Copyright 2024 Veeva Systems